Le Lézard
Classified in: Health, Science and technology
Subject: TRI

FDA Qualifies Safety Biomarker Panel Developed And Validated By Pacific Biomarkers For Kidney Injury


SEATTLE and WASHINGTON, Nov. 6, 2018 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA), announced that the qualification of the Predictive Safety Testing Consortium (PSTC) Safety Biomarker Panel was approved for use in conjunction with standard of care methods to aid in the detection of kidney tubular injury in Phase 1 trials. The panel, developed and validated at Pacific Biomarkers, is comprised of six urinary biomarkers ?

Clusterin (CLU), Cystatin-C (CysC), Kidney Injury Molecule-1 (KIM-1), N-acetyl-beta-D-glucosaminidase (NAG), Neutrophil Gelatinase-Associated Lipocalin (NGAL), and Osteopontin (OPN).

The results from each biomarker in the panel can be used to derive a composite measure, which is used to predict the potential severity of kidney tubular injury by the investigated drug. This qualification panel is approved by FDA for testing in first-in-human studies.

"I'm very proud of the overwhelming amount of work that Pacific Biomarkers has dedicated toward the analytical and clinical study data used to support this Qualification. This panel at Pacific Biomarkers is the new Gold Standard toward establishing renal tubular safety of a drug in early development." ? Dr. Candace Adamo

This panel is currently available through Pacific Biomarkers. More information is available at www.pacbio.com  

Pacific Biomarkers is a CAP accredited, CLIA certified biomarker testing services provider, supporting pharmaceutical, biotech and in-vitro diagnostic (IVD) manufacturing companies through preclinical and Phase I-IV studies of drug and IVD development.

The Predictive Safety Testing Consortium brings together pharmaceutical companies to share and validate innovative safety testing methods under advisement of the FDA, EMA and PMDA. The mission of the PSTC is to identify new and improved safety testing methods and submit them for formal regulatory qualification by the FDA, EMA and PMDA.

 

SOURCE Pacific Biomarkers


These press releases may also interest you

at 09:00
Guidewire announced that Guidewire PartnerConnect Consulting and Global Premier partner, Ernst & Young LLP (EY), has achieved the global Migration Acceleration Specialization. Partners who have earned this specialization have demonstrated the...

at 08:55
Shield AI, Inc., a defense technology company building the world's best AI pilot, and Kratos Defense & Security Solutions, Inc. , a Technology Company in the Defense, National Security and Global Markets and an industry-leading provider of...

at 08:45
HYAS Infosec, the adversary infrastructure platform provider that offers unparalleled visibility, protection, and security against all kinds of malware and attacks, today announced that it has been awarded three top recognitions from Security Today's...

at 08:44
Understanding the underlying mechanisms of normal and pathological cellular processes is essential for developing new drugs. Fortunately, modern techniques and experimental methods have greatly accelerated progress. The latest issue of JPA features...

at 08:44
Environmental problems caused by population explosion such as global warming, natural resource depletion, deforestation, water shortage and plastic pollution are getting severe in the world. Regarding plastic pollution, micro-plastics, nano-plastics...

at 08:43
WIN (Women In Negotiation) is pleased to announce Walmart Connect as its presenting sponsor - for its eighth annual WIN Summit to be held Thursday, May 30, 2024 in New York City....



News published on and distributed by: